The most crucial RTKs include epidermal growth factor receptor (EGFR), insulin like growth factor receptor (IGFR), platelet-derived growth factor receptor (PDGFR), vascular endothelial growth factor (VEGF) and nerve growth factor receptor (NGFR), which are the current targets in developing cancer therapeutics particularly for GBM. This evidence concerns the gene EGFR and glioblastoma.